These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 24162815

  • 21. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [Abstract] [Full Text] [Related]

  • 22. New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.
    Rolfo C, Raez L.
    Lab Invest; 2017 Nov; 97(11):1268-1270. PubMed ID: 29085074
    [Abstract] [Full Text] [Related]

  • 23. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
    Kyker-Snowman K, Hughes RM, Yankaskas CL, Cravero K, Karthikeyan S, Button B, Waters I, Rosen DM, Dennison L, Hunter N, Donaldson J, Christenson ES, Konstantopoulos K, Hurley PJ, Croessmann S, Park BH.
    Breast Cancer Res Treat; 2020 Feb; 179(3):631-642. PubMed ID: 31823098
    [Abstract] [Full Text] [Related]

  • 24. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS, Lassen U.
    Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
    [Abstract] [Full Text] [Related]

  • 25. NTRK Gene Fusion Detection in Atypical Spitz Tumors.
    Cappellesso R, Nozzoli F, Zito Marino F, Simi S, Castiglione F, De Giorgi V, Cota C, Senetta R, Scognamiglio G, Anniciello AM, Cesinaro AM, Mandalà M, Gianatti A, Valente MG, Valeri B, Sementa AR, Ricci C, Corti B, Roviello G, Dei Tos AP, Franco R, Massi D.
    Int J Mol Sci; 2021 Nov 15; 22(22):. PubMed ID: 34830218
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. CD74-NRG1 fusions in lung adenocarcinoma.
    Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas SA, Yatabe Y, Thomas RK.
    Cancer Discov; 2014 Apr 15; 4(4):415-22. PubMed ID: 24469108
    [Abstract] [Full Text] [Related]

  • 28. Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.
    Agaram NP, Zhang L, Sung YS, Chen CL, Chung CT, Antonescu CR, Fletcher CD.
    Am J Surg Pathol; 2016 Oct 15; 40(10):1407-16. PubMed ID: 27259011
    [Abstract] [Full Text] [Related]

  • 29. Prognostic value and characterization of NTRK1 variation by fluorescence in situ hybridization in esophageal squamous cell carcinoma.
    Yu Z, Wang H, Song Q, Huang J, Xu J, Su J, Wang H, Tan L, Wang X, Jiang Z, Chen W, Jiang D, Hou Y.
    J Cancer Res Clin Oncol; 2021 Oct 15; 147(10):3113-3121. PubMed ID: 33963905
    [Abstract] [Full Text] [Related]

  • 30. STRN3-NTRK1: A Novel NTRK1 Oncogenic Fusion in a Patient with Lung Adenocarcinoma.
    Lu R, Qi C, Xiao M, Cai S, Zheng M.
    J Thorac Oncol; 2020 Feb 15; 15(2):e23-e24. PubMed ID: 32127185
    [No Abstract] [Full Text] [Related]

  • 31. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.
    Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Brown J, Fujii Y.
    Mol Clin Oncol; 2014 Sep 15; 2(5):725-730. PubMed ID: 25054037
    [Abstract] [Full Text] [Related]

  • 32. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
    Xu H, Zhang Q, Liang L, Li J, Liu Z, Li W, Yang L, Yang G, Xu F, Ying J, Zhang S, Wang Y.
    Cancer Med; 2020 May 15; 9(10):3328-3336. PubMed ID: 32168429
    [Abstract] [Full Text] [Related]

  • 33. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 15; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 34. Lung cancer: drug-sensitivity--time for a rearrangement?
    Hutchinson L.
    Nat Rev Clin Oncol; 2013 Dec 15; 10(12):670. PubMed ID: 24217201
    [No Abstract] [Full Text] [Related]

  • 35. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
    Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW.
    J Clin Oncol; 2019 Feb 20; 37(6):513-524. PubMed ID: 30592640
    [Abstract] [Full Text] [Related]

  • 36. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes.
    Suurmeijer AJH, Dickson BC, Swanson D, Zhang L, Sung YS, Cotzia P, Fletcher CDM, Antonescu CR.
    Genes Chromosomes Cancer; 2018 Dec 20; 57(12):611-621. PubMed ID: 30276917
    [Abstract] [Full Text] [Related]

  • 37. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 38. Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.
    Wang B, Gao Y, Huang Y, Ou Q, Fang T, Tang C, Wu X, Shao YW.
    Clin Lung Cancer; 2019 May 15; 20(3):e233-e237. PubMed ID: 30691963
    [No Abstract] [Full Text] [Related]

  • 39. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK, Shaik S, Satya Pratap VVV, Yadlapalli P, Yanamandra M, Mitra S.
    Anal Biochem; 2018 Mar 15; 545():78-83. PubMed ID: 29360440
    [Abstract] [Full Text] [Related]

  • 40. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
    Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A.
    Nat Commun; 2017 Jul 11; 8():15987. PubMed ID: 28695888
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.